{
  "Study_ID": "Sinh_2022",
  "First_Author": "Sinh, C.T.",
  "Year": "2022",
  "Country": "Vietnam",
  "Study_Design": "Prospective Cohort",
  "Risk_of_Bias": "Moderate",
  "Diagnostic_Criteria": "Vietnamese Ministry of Health criteria (epidemiological, clinical, laboratory)",
  "Total_Sample_Size": "60",
  "Treatment_Group_N": "60",
  "Control_Group_N": "0",
  "Age_Mean_SD": "50.17Â±10.03",
  "Male_Percentage": "86.7",
  "Female_Percentage": "13.3",
  "Other_Demographics": "Farmers (65.5%), Other occupations (35.5%)",
  "Headache_Percentage": "90.0",
  "Focal_Seizures_Percentage": "68.3",
  "Other_Symptoms": "Memory loss (19.2%), Fainting (28.3%), Limb numbness (20.0%), Vomiting/nausea (15.0%), Balance disorders (10.0%), Muscle weakness (10.0%), Blurred vision (3.3%)",
  "Treatment_Type": "Albendazole + Initial Praziquantel",
  "Albendazole_Dose": "15 mg/kg/day",
  "Treatment_Duration_Days": "90",
  "Number_of_Cycles": "3",
  "Cycle_Interval_Days": "20",
  "Praziquantel_Dose": "20 mg/kg",
  "Corticosteroid_Type": "Not specified",
  "Antiepileptic_Drug": "As needed",
  "Follow_up_Duration_Months": "6",
  "Imaging_Schedule": "MRI follow-up",
  "Complete_Resolution_Percentage": "43.3",
  "Partial_Resolution_Percentage": "51.7",
  "No_Change_Percentage": "5.0",
  "Seizure_Reduction_Percentage": "56.1",
  "Elevated_Liver_Enzymes_Percentage": "Course 1: AST 66.7%, ALT 83.3%; Course 2: AST 75%, ALT 91.7%; Course 3: AST 85%, ALT 81.7%",
  "Other_AE": "Headaches, Vomiting, Seizure exacerbation",
  "Comments": "Long-course albendazole (3x30 days) showed good efficacy with 95% showing radiological improvement. Higher complete resolution rate (43.3%) compared to typical 25-37% with shorter courses. Liver enzyme elevations were common but mostly mild and reversible."
}